Beyond Compliance: AJNA BioSciences' Joel Stanley on Bringing Botanical Medicine Through the FDA Pathway

In this episode of Beyond Compliance, host Otis Johnson, PhD, MPA, founder and principal consultant at Vantix Operations, talks with Joel Stanley, CEO of AJNA BioSciences and co-founder of Charlotte's Web, about what it takes for botanical therapies to earn the same credibility as conventional medicines.

Drawing on his experience developing CBD products for children with treatment-resistant epilepsy, Stanley explains why minimum dietary supplement standards fail to address the core challenge of plant-based medicine: variability. Differences in genetics, growing region, and cultivation practices can meaningfully change a plant's chemical makeup, even when the label stays the same, undermining reproducibility and physician confidence.

Stanley describes how AJNA leverages decades of real-world use and observational data on cannabinoids and psilocybin to de-risk clinical development, while acknowledging the limits of relying on anecdotal evidence shaped by health fads. He contrasts Charlotte's Web, which remained a supplement, with GW Pharmaceuticals' Epidiolex, which pursued FDA approval and now generates over a billion dollars annually with insurance coverage, to illustrate the commercial and access advantages of the harder regulatory path. The conversation closes with Stanley's view that moving beyond compliance means tightening control over botanical raw materials and pursuing rigorous standardization, regardless of whether a company chooses the supplement or pharmaceutical route.

Key takeaways

• Genetics, growing region, and cultivation practices can substantially change a plant's chemical composition even when the product label stays the same, making consistency the central challenge for botanical medicine.
• Decades of real-world use and observational data can de-risk clinical development for botanical drugs, though placebo effects and health fads make that evidence a double-edged advantage.
• Charlotte's Web built a five-year market head start as a supplement, but GW Pharmaceuticals' FDA-approved Epidiolex now generates over $1 billion annually because physicians can prescribe it and insurance covers it.
• Moving beyond compliance means tightening control over botanical raw material sourcing and testing for phytomolecules, whether or not a company ultimately pursues the pharmaceutical pathway.